<DOC>
	<DOCNO>NCT01991678</DOCNO>
	<brief_summary>The purpose study investigate PK safety NKTR-102 patient mild , moderate , severe hepatic impairment .</brief_summary>
	<brief_title>A Study Cancer Patients With Hepatic Impairment Evaluate Pharmacokinetics Safety NKTR-102 ( Etirinotecan Pegol )</brief_title>
	<detailed_description>Safety PK data patient mild , moderate , severe hepatic impairment compare control group consist patient normal hepatic function .</detailed_description>
	<mesh_term>Liver Diseases</mesh_term>
	<criteria>Relapsed progressive advanced solid tumor malignancy Measurable nonmeasurable disease Eastern Cooperative Oncology Group ( ECOG ) performance status 02 Life expectancy great 3 month Resolution acute toxic effect prior chemotherapy , cancer treatment Adequate bone morrow kidney function No sign decompensated liver cirrhosis ascites require therapeutic paracentesis Agree use adequate contraception Previous chemotherapy , immunotherapy , chemoembolization , target therapy investigational agent malignancy within 4 week prior day 1 Cytochrome P450 CYP3A4 inducer inhibitor within 4 week prior day 1 Intake grapefruit , grapefruit juice , Seville oranges , product contain grapefruit Seville oranges within 14 day prior day 1 UGT1A1 genotype TA 7 allele ( homozygous UGT1A1*28 ) TA 8 either one allele ( hetero homozygous UGT1A1*37 ) Major surgery within 4 week prior day 1 Undergone liver organ transplant Concurrent treatment anticancer therapy Untreated central nervous system metastases Ongoing active infection Chronic acute GI disorder result diarrhea Pregnancy lactation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>